Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics
- PMID: 38588769
- PMCID: PMC11536471
- DOI: 10.1016/j.jmoldx.2024.03.007
Cost-Effective and Scalable Clonal Hematopoiesis Assay Provides Insight into Clonal Dynamics
Abstract
Clonal hematopoiesis of indeterminate potential (CHIP) is a common age-related phenomenon in which hematopoietic stem cells acquire mutations in a select set of genes commonly mutated in myeloid neoplasia which then expand clonally. Current sequencing assays to detect CHIP mutations are not optimized for the detection of these variants and can be cost-prohibitive when applied to large cohorts or to serial sequencing. In this study, an affordable (approximately US $8 per sample), accurate, and scalable sequencing assay for CHIP is introduced and validated. The efficacy of the assay was demonstrated by identifying CHIP mutations in a cohort of 456 individuals with DNA collected at multiple time points in Vanderbilt University's biobank and quantifying clonal expansion rates over time. A total of 101 individuals with CHIP/clonal cytopenia of undetermined significance were identified, and individual-level clonal expansion rate was calculated using the variant allele fraction at both time points. Differences in clonal expansion rate by driver gene were observed, but there was also significant individual-level heterogeneity, emphasizing the multifactorial nature of clonal expansion. Additionally, mutation co-occurrence and clonal competition between multiple driver mutations were explored.
Copyright © 2024 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosure Statement M.R.S. has received honoraria for advisory board membership or consultancy from Bristol Myers Squibb, CTI, Forma, Geron, GlaxoSmithKline/Sierra Oncology, Karyopharm, Ryvu Therapeutics, and Taiho Pharmaceutical; has received research funding from ALX Oncology, Astex Pharmaceuticals, Incyte Corporation, Takeda, and TG Therapeutics; holds equity in Empath Biosciences, Karyopharm, and Ryvu Therapeutics; and has been reimbursed for travel expenses by Astex. A.G.B. has received honoraria for advisory board membership from, and holds equity in, TenSixteen Bio.
Figures




Update of
-
Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics.medRxiv [Preprint]. 2023 Nov 9:2023.11.08.23298270. doi: 10.1101/2023.11.08.23298270. medRxiv. 2023. Update in: J Mol Diagn. 2024 Jul;26(7):563-573. doi: 10.1016/j.jmoldx.2024.03.007. PMID: 37986782 Free PMC article. Updated. Preprint.
References
-
- Greider C.W. Telomeres and senescence: the history, the experiment, the future. Curr Biol. 1998;8:R178–R181. - PubMed
-
- Jaiswal S., Fontanillas P., Flannick J., Manning A., Grauman P.V., Mar B.G., Lindsley R.C., Mermel C.H., Burtt N., Chavez A., Higgins J.M., Moltchanov V., Kuo F.C., Kluk M.J., Henderson B., Kinnunen L., Koistinen H.A., Ladenvall C., Getz G., Correa A., Banahan B.F., Gabriel S., Kathiresan S., Stringham H.M., McCarthy M.I., Boehnke M., Tuomilehto J., Haiman C., Groop L., Atzmon G., Wilson J.G., Neuberg D., Altshuler D., Ebert B.L. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371:2488–2498. - PMC - PubMed
-
- Lee-Six H., Øbro N.F., Shepherd M.S., Grossmann S., Dawson K., Belmonte M., Osborne R.J., Huntly B.J.P., Martincorena I., Anderson E., O’Neill L., Stratton M.R., Laurenti E., Green A.R., Kent D.G., Campbell P.J. Population dynamics of normal human blood inferred from somatic mutations. Nature. 2018;561:473–478. - PMC - PubMed
Publication types
MeSH terms
Grants and funding
- S10 OD017985/OD/NIH HHS/United States
- UL1 TR000445/TR/NCATS NIH HHS/United States
- T32 GM145734/GM/NIGMS NIH HHS/United States
- DP5 OD029586/OD/NIH HHS/United States
- F30 DK127699/DK/NIDDK NIH HHS/United States
- S10 RR025141/RR/NCRR NIH HHS/United States
- R01 CA262287/CA/NCI NIH HHS/United States
- T32 GM139800/GM/NIGMS NIH HHS/United States
- T32 GM007347/GM/NIGMS NIH HHS/United States
- P30 CA068485/CA/NCI NIH HHS/United States
- S10 OD025092/OD/NIH HHS/United States
- UL1 RR024975/RR/NCRR NIH HHS/United States
- U01 OH012271/OH/NIOSH CDC HHS/United States
LinkOut - more resources
Full Text Sources